Remaining Questions With Multiple Myeloma Treatment
September 15th 2017Robert Orlowski, MD, PhD, Florence Maude Thomas Cancer Research professor and chair, ad interim, Department of Lymphoma & Myeloma at The University of Texas MD Anderson Cancer Center, discusses remaining questions with multiple myeloma treatment.
Watch
Combining an Anti-LAG-3 Antibody With Nivolumab in Melanoma
September 13th 2017Paolo A. Ascierto, MD, director at the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Tumor Institute Fondazione G. Pascale, discusses the initial efficacy findings for the anti-LAG-3 antibody BMS-986016 plus nivolumab in patients with immunotherapy-relapsed/refractory melanoma.
Watch
Dr. Langer Discusses Current Treatment Strategies for Patients With Non-Driver Nonsquamous NSCLC
September 13th 2017Corey J. Langer, MD, Perelman Center for Advanced Medicine, Hospital of the University of Pennsylvania, discusses current treatment strategies for patients with non-driver nonsquamous non-small cell lung cancer (NSCLC).
Watch
Dr. Langer Discusses Ongoing Clinical Trials for Patients With Non-Driver NSCLC
September 13th 2017Corey J. Langer, MD, Perelman Center for Advanced Medicine; Hospital of the University of Pennsylvania, discusses ongoing clinical trials for patients with non-driver non-small cell lung cancer (NSCLC).
Watch
Dr. Langer Discusses Remaining Challenges With the Non-Driver NSCLC Population
September 13th 2017Corey J. Langer, MD, Perelman Center for Advanced Medicine; Hospital of the University of Pennsylvania, discusses remaining challenges in the treatment of patients with non-driver non-small cell lung cancer.
Watch
Dr. Jagannath Discusses the STORM and STOMP Trials for Patients With Multiple Myeloma
September 12th 2017Sundar Jagannath, MDDS, professor, Medicine, Hematology, and Medical Oncology, Mount Sinai Hospital, discusses the STORM and STOMP clinical trials in patients with multiple myeloma.
Watch
Significance of the Phase III FLAURA Study in EGFR+ NSCLC
September 11th 2017Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the randomized phase III FLAURA study of frontline osimertinib (Tagrisso) in patients with EGFR-mutant non-small cell lung cancer.
Watch
An Update on Avelumab as Monotherapy for Urothelial Carcinoma
September 11th 2017Andrea Apolo, MD, medical oncologist at the National Cancer Institute and chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses the recent updates presented at the 2017 ESMO Annual Congress regarding avelumab (Bavencio) monotherapy for patients with urothelial carcinoma.
Watch
Avelumab Treatment in Patients With Metastatic Merkel Cell Carcinoma
September 10th 2017Celeste Lebbé, MD, from the Hôpital Saint Louis, in Paris, France, discusses avelumab treatment in chemotherapy-naive patients with distant metastatic Merkel cell carcinoma during the 2017 ESMO Annual Congress.
Watch
Dr. Luke Discusses the Combination of Epacadostat and Pembrolizumab in Melanoma
September 9th 2017Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses the combination of epacadostat and pembrolizumab (Keytruda) for the treatment of melanoma during the 2017 ESMO Annual Congress.
Watch
Toxicities Associated With Rucaparib for the Treatment of Ovarian Cancer
September 8th 2017Jonathan Ledermann, MD, professor of medical oncology in the University College London Cancer Institute and director of Cancer Research UK and UCL Cancer Trials Centre, discusses the toxicities associated with rucaparib (Rubraca) for the treatment of ovarian cancer.
Watch